High Potency API (HPAPI) Contract Manufacturing Market to Grow with a CAGR of 8.42% through 2028
Rising
demand
for precision medicine are expected to drive the Global High Potency API
(HPAPI) Contract Manufacturing Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “High Potency
API (HPAPI) Contract Manufacturing Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global High Potency API (HPAPI)
Contract Manufacturing Market stood at USD 7.15 billion in 2022 and is
anticipated to grow with a CAGR of 8.42% in the forecast period, 2024-2028. The
Global High Potency API (HPAPI) Contract Manufacturing Market is experiencing
robust growth, driven by a confluence of factors that underscore its critical
role in the pharmaceutical and biotechnology industries. HPAPIs, characterized
by their high pharmacological activity and low effective doses, have become
instrumental in the development of targeted therapies for various medical
conditions. As the demand for precision medicine and specialized treatments
continues to rise, so does the significance of HPAPIs and the contract
manufacturing services that support their production. One of the primary drivers of the HPAPI contract
manufacturing market is the escalating prevalence of chronic and rare diseases.
These conditions often require highly potent drugs capable of precise targeting
and minimal side effects. HPAPIs fit this bill perfectly, making them
indispensable for the pharmaceutical industry. With an aging global population
and an increase in lifestyle-related diseases, the demand for HPAPI-based
medications is expected to remain strong.
Many blockbuster drugs have seen their patents expire
in recent years, opening the door for generic and biosimilar competition. To
maintain a competitive edge, pharmaceutical companies are turning to the
development of innovative, highly potent drugs that offer distinct therapeutic
advantages. Contract manufacturing organizations (CMOs) specializing in HPAPIs
are being enlisted to help bring these new drugs to market efficiently and
cost-effectively. Developing and manufacturing HPAPIs in-house requires substantial
investments in specialized facilities, equipment, and highly trained personnel.
Outsourcing to CMOs specializing in HPAPIs allows pharmaceutical companies to
reduce capital expenditures and leverage the expertise and infrastructure of
these specialized service providers. This outsourcing trend is expected to
persist as companies seek to optimize their operational costs.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "High Potency API (HPAPI) Contract Manufacturing Market.”
The competitive landscape of the HPAPI contract
manufacturing market has spurred continuous innovation. CMOs are constantly
enhancing their manufacturing technologies, improving process efficiency, and
reducing production costs. Advances in containment technologies, such as
isolators and gloveboxes, have made it possible to handle HPAPIs with even
greater precision and safety. These technological advancements have not only
boosted the market but have also led to more effective and safer HPAPI-based
medications.
The Global High Potency API (HPAPI) Contract
Manufacturing Market is segmented into Formulation, End Use, Regional
Distribution, And Company.
Based on the Formulation, the Injectables emerged as
the dominant segment in the global market for Global High Potency API (HPAPI)
Contract Manufacturing Market in 2022 Injectable medications, which include
solutions, suspensions, and lyophilized powders, often comprise complex and
highly potent compounds. These drugs are commonly used in critical medical
situations, such as cancer treatment, autoimmune diseases, and emergency care,
where precision and reliability are of utmost importance. As a result, they
frequently require HPAPIs to achieve the desired therapeutic effects. The
demand for injectables has been on the rise due to the increasing focus on
advanced therapies, including biologics, monoclonal antibodies, and cell-based
treatments. Many of these therapies rely on HPAPIs to achieve their desired
pharmacological activity and specificity, further driving the demand for HPAPI
contract manufacturing services.
Based on the End Use, the Oncology segment emerged as
the dominant player in the global market for Global High Potency API (HPAPI)
Contract Manufacturing Market in 2022. The global prevalence of cancer
continues to increase, making it one of the most prevalent and life-threatening
diseases. As a result, the demand for oncology drugs, including targeted
therapies and immunotherapies, is continuously growing. Many of these advanced
therapies rely on HPAPIs for their high potency and precision in targeting cancer
cells. The trend toward precision medicine has gained traction in oncology.
Healthcare providers increasingly seek to tailor cancer treatments to the
specific genetic or molecular characteristics of individual patients and their
tumors. This approach often involves the development of highly specialized
medications that require HPAPIs for their precision and efficacy. Many of the innovative oncology treatments fall under
the category of biologics and monoclonal antibodies. These complex therapies,
designed to target specific cancer markers or pathways, frequently employ
HPAPIs in their formulations. The demand for these biopharmaceuticals
contributes significantly to the need for HPAPI contract manufacturing
services.
North America emerged as the dominant player in the
global High Potency API (HPAPI) Contract Manufacturing Market in 2022, holding
the largest market share. North America, particularly the United States, boasts
a robust and well-established pharmaceutical industry. The region is home to
numerous pharmaceutical companies that are at the forefront of drug development
and innovation. This industry strength creates a high demand for HPAPI contract
manufacturing services to support the production of specialized and
high-potency medications. Oncology remains a significant therapeutic area of
focus in North America. The prevalence of cancer and the continuous development
of novel oncology drugs have driven the demand for HPAPIs, which are often
integral to the formulation of precise and effective cancer treatments. North
American pharmaceutical companies are leaders in oncology research and
development, further bolstering the demand for HPAPI contract manufacturing.
Major companies operating in Global High Potency
API (HPAPI) Contract Manufacturing Market are:
- Catalent, Inc.
- Lonza Group
- Piramal Pharma Solutions
- Pfizer CentreOne
- Gentec Pharmaceutical Group
- AbbVie Contract Manufacturing
- Corden Pharma International
- Curia Global, Inc.
- Merck Group (SigmaAldrich Co., LLC)
- Polpharma Group
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global High
Potency API (HPAPI) Contract Manufacturing Market is poised for substantial
growth in the coming years. Anticipated advancements in pharmaceutical research
and development, particularly in precision medicine and oncology, are expected
to drive the demand for HPAPIs. The increasing prevalence of chronic diseases,
including cancer, coupled with a rising global population, will further boost
the need for highly potent and specialized medications. Moreover, the
pharmaceutical industry's ongoing efforts to expedite drug development
timelines and address unmet medical needs will lead to a greater reliance on
HPAPI contract manufacturing services. As regulatory authorities continue to
emphasize safety and quality standards, contract manufacturing organizations
(CMOs) with expertise in HPAPI production will play an indispensable role in
meeting these stringent requirements.” said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based management consulting firm.
“High Potency API (HPAPI) Contract Manufacturing
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
2018-2028 Segmented By Formulation (Injectables, Oral Solids, Lotions, Others),
By End Use (Oncology, Antidiabetics, Autoimmune, Others) By Region and
Competition”, has evaluated the future growth potential of Global High Potency API
(HPAPI) Contract Manufacturing Market and provides statistics & information
on market size, structure and future market growth. The report intends to
provide cutting-edge market intelligence and help decision makers take sound
investment decisions. Besides, the report also identifies and analyzes the
emerging trends along with essential drivers, challenges, and opportunities in
Global High Potency API (HPAPI) Contract Manufacturing Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com